930785-23-2

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 188582-62-9 4-bromo-2-fluorobenzyl alcohol 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 

Downstream Products

• 1008517-98-3 tert-butyl-(2-fluoro-4-iodo-benzyloxy)-dimethyl-silane 
• 1272974-20-5 (R)-tert-butyl 4-(5-(2-fluoro-4-(methylsulfonylmethyl)benzyloxy)pyrimidin-2-yl)-3-methylpiperazine-1-carboxylate 
• 1272973-54-2 3-(trifluoromethyl)oxetan-3-yl (3R)-4-[5-({2-fluoro-4-[(methylsulfonyl)methyl]benzyl}oxy)pyrimidin-2-yl]-3-methylpiperazine-1-carboxylate 
• 1402586-83-7 2-(3-fluoro-4-(hydroxymethyl)phenyl)propanoic acid 
• 937636-18-5 methyl 3-fluoro-4-(hydroxymethyl)benzoate 
• 128577-47-9 methyl 4-(bromomethyl)-3-fluorobenzoate 

Relevant academic research and scientific papers

CRF RECEPTOR ANTAGONISTS AND METHODS OF USE

Compounds are provided herein, as well as related preparations, compositions and methods for treating diseases and/or disorders that would benefit from the same such as congenital adrenal hyperplasia (CAH).

ANTIMICROBIAL COMPOUNDS AND METHODS

The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-negative bacteria. Also disclosed are processes and intermediates for making the compounds.

SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are 4-aminoisoindoline-1,3-dione compounds having the following structure: wherein R, Ring A, and n are as defined herein, compositions comprising an effective amount of a 4-aminoisoindoline-1,3-dione compound, and methods for treating or preventing disorders.

Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease

We have identified chemical probes that act as dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors (>1 log unit difference versus class I HDACs) to decipher the contribution of HDAC isoforms to the positive impact of dua

SUBSTITUTED OXAZOLE- AND THIAZOLE-BASED CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS II

The invention relates to oxazole and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

DIARYL KETIMINE DERIVATIVE

Provided is a compound of a formula (I): [wherein R1a and R1b are the same or different, representing a hydrogen atom, etc.; R2a and R2b are the same or different, representing a hydrogen atom, etc., or R2a and R2b, taken together, form -CH2CH2-, R3a and R3b are the same or different, representing a hydrogen atom, etc.; or R3a and R3b, taken together, form - CH2CH2-etc.; Y1 and Y2 represent -C(R)2-, etc.; Z represents OR, NR2, etc.; R represents a hydrogen atom, a C1-6 alkyl group, etc.; Ar1 represents a 6-membered aromatic carbocyclic group, etc.; Ar2 represents a 6-membered aromatic carbocyclic group, etc; A3 represents a 6-membered aromatic carbocyclic group etc.]. The compound is useful as a medicine for central disorders, cardiovascular disorders, metabolic disorders.

PYRIDONE AND PYRIDAZINONE DERIVATIVES AS MCH ANTAGONISTS

The present invention relates to pyridone and pyridazinone derivatives as listed in claim 1 including their salts. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of thei

NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS

The present invention relates to compounds of general formula (I) wherein the groups and radicals B, k, L, U,V, W, X, Y, Z, R1, R2, have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH- receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

NOVEL ADENINE COMPOUND

An adenine compound useful for a medicament represented by the following formula (1): , wherein A1 and A2 are independently, optionally substituted cyclic aromatic hydrocarbon group or optionally substituted aromatic heterocyclic gro